Seeking Alpha " SRPT 62 WEEK DATA OUT-TO PROPEL SHARES,EARLY APPROVAL' link
Biotech Stocks With Important Catalysts Approaching
December 7, 2012
Sarepta will announced 62 week clinical data confirming the 48 week data and seek accelerated approval from the FDA for eteplirsen. The release of the 62 week data could occur anytime and, if positive, would certainly propel the stock and give Sarepta more leverage for accelerated approval from the FDA.